
Wellington Management
Description
Wellington Management is a venerable global investment management firm, renowned for its comprehensive investment capabilities spanning public and private markets. Established in 1928, the firm primarily serves a diverse institutional client base, including pension funds, endowments, sovereign wealth funds, and financial advisors. With over $1.2 trillion in assets under management as of late 2023, Wellington Management is one of the largest independent investment firms globally, distinguished by its deep fundamental research and long-term investment horizon.
While not a traditional early-stage venture capital firm, Wellington Management actively participates in the private markets, focusing predominantly on later-stage growth equity and pre-IPO investments. Their strategy involves identifying and backing mature, high-growth private companies that are often on the cusp of significant expansion or public market entry. The firm leverages its extensive research capabilities and sector expertise, particularly in areas like healthcare, biotechnology, and disruptive technologies, to identify promising opportunities. They often invest alongside other large institutional investors in substantial funding rounds.
Wellington's approach to private investments is characterized by its scale and a focus on significant capital deployment. Typical first checks for their private growth equity investments are substantial, generally ranging from approximately $25 million for a meaningful stake in a growth-stage company, up to $150 million or more for larger, strategic pre-IPO opportunities. Their participation in these rounds provides not only capital but also the strategic insights and network of a globally recognized financial institution, making them a valuable partner for companies seeking to scale and eventually transition to public markets.
Investor Profile
Wellington Management has backed more than 280 startups, with 33 new investments in the last 12 months alone. The firm has led 91 rounds, about 33% of its total and boasts 120 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series C, Series B, Series D rounds (top funding stages).
- Majority of deals are located in United States, India, United Kingdom.
- Strong thematic focus on Biotechnology, Health Care, Medical.
- Led 11 rounds in the past year.
- Typical check size: $25M – $150M.
Stage Focus
- Series C (19%)
- Series B (17%)
- Series D (13%)
- Series E (11%)
- Post Ipo Equity (11%)
- Series F (7%)
- Series A (6%)
- Series Unknown (6%)
- Private Equity (3%)
- Seed (2%)
Country Focus
- United States (86%)
- India (4%)
- United Kingdom (3%)
- Brazil (1%)
- China (1%)
- France (1%)
- Saudi Arabia (1%)
Industry Focus
- Biotechnology
- Health Care
- Medical
- Therapeutics
- Software
- Pharmaceutical
- Fintech
- Financial Services
- Biopharma
- Life Science
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.